305 related articles for article (PubMed ID: 24477544)
1. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
[TBL] [Abstract][Full Text] [Related]
2. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
3. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
[TBL] [Abstract][Full Text] [Related]
4. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
Tatarkiewicz K; Belanger P; Gu G; Parkes D; Roy D
Diabetes Obes Metab; 2013 May; 15(5):417-26. PubMed ID: 23163898
[TBL] [Abstract][Full Text] [Related]
5. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
6. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.
Thomson SC; Kashkouli A; Singh P
Am J Physiol Renal Physiol; 2013 Jan; 304(2):F137-44. PubMed ID: 23019232
[TBL] [Abstract][Full Text] [Related]
8. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
9. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
10. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
Mul JD; Begg DP; Barrera JG; Li B; Matter EK; D'Alessio DA; Woods SC; Seeley RJ; Sandoval DA
Am J Physiol Regul Integr Comp Physiol; 2013 Jul; 305(1):R68-77. PubMed ID: 23616105
[TBL] [Abstract][Full Text] [Related]
11. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
12. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
Maida A; Lovshin JA; Baggio LL; Drucker DJ
Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
[TBL] [Abstract][Full Text] [Related]
13. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
Ionut V; Zheng D; Stefanovski D; Bergman RN
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
Owens DR; Monnier L; Bolli GB
Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
[TBL] [Abstract][Full Text] [Related]
15. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
16. Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice.
Burmeister MA; Ferre T; Ayala JE; King EM; Holt RM; Ayala JE
Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E334-43. PubMed ID: 22094469
[TBL] [Abstract][Full Text] [Related]
17. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
Briones M; Bajaj M
Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
[TBL] [Abstract][Full Text] [Related]
19. Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ.
Cabou C; Vachoux C; Campistron G; Drucker DJ; Burcelin R
Diabetes; 2011 Sep; 60(9):2245-56. PubMed ID: 21810595
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
